Wolverine Asset Management’s Blueprint Medicines BPMC Stock Holding History

Wolverine Asset Management’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-5,191	Closed	-$665K	–	1629
2025 Q2	$665K	Buy	+5,191	New	+$539K	0.01%	809
2021 Q3	–	Sell	-1,455	Closed	-$127K	–	2013
2021 Q2	$127K	Buy	+1,455	New	+$133K	﹤0.01%	1400
2020 Q3	–	Sell	-11	Closed	–	–	1568
2020 Q2	$0	Buy	+11	New	+$744	﹤0.01%	1542

Other funds holding BPMC

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Wolverine Asset Management's BPMC Position: Q3 2025 in Review

Wolverine Asset Management sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 5,191 shares — an estimated $665K sold.

Wolverine Asset Management first reported a position in BPMC in Q2 2020 and held it in 3 quarters. The position peaked at $665K in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

Wolverine Asset Management reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
Wolverine Asset Management sold 5,191 Blueprint Medicines shares in Q3 2025, an estimated $665K.
Wolverine Asset Management first reported a position in Blueprint Medicines in Q2 2020 and held it in 3 quarters.
Wolverine Asset Management's Blueprint Medicines position peaked at $665K in Q2 2025.
5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Wolverine Asset Management's 13F filing for Q3 2025, filed 28 Oct 2025.